LivaNova Acquires Tandem Diabetes Care for $1.3B
Ticker: LIVN · Form: 8-K · Filed: 2024-03-06T00:00:00.000Z
Sentiment: bullish
Topics: acquisition, healthcare, medical-devices, diabetes-care
TL;DR
LivaNova just bought Tandem Diabetes Care for $1.3B to boost its diabetes tech game.
AI Summary
LivaNova PLC announced on March 5, 2024, that it has completed the acquisition of all outstanding shares of Tandem Diabetes Care, Inc. for $13.00 per share in cash, representing a total transaction value of approximately $1.3 billion. This strategic move aims to enhance LivaNova's position in the diabetes care market.
Why It Matters
This acquisition significantly expands LivaNova's presence in the diabetes technology sector, potentially leading to new product offerings and market share growth.
Risk Assessment
Risk Level: medium — The acquisition involves a significant financial outlay and integration risks, and the success of the combined entity depends on market reception and competitive pressures.
Key Numbers
- $1.3B — Acquisition Value (Total cash consideration for Tandem Diabetes Care)
- $13.00 — Price Per Share (Cash paid for each share of Tandem Diabetes Care)
Key Players & Entities
- LivaNova PLC (company) — Acquiring company
- Tandem Diabetes Care, Inc. (company) — Acquired company
- $1.3 billion (dollar_amount) — Total transaction value
- $13.00 (dollar_amount) — Price per share
- March 5, 2024 (date) — Date of announcement
FAQ
What is the primary strategic rationale behind LivaNova's acquisition of Tandem Diabetes Care?
The acquisition aims to enhance LivaNova's position and offerings within the diabetes care market.
What was the total value of the transaction?
The total transaction value was approximately $1.3 billion.
What was the price per share paid by LivaNova?
LivaNova paid $13.00 per share in cash for all outstanding shares of Tandem Diabetes Care.
When was the acquisition announced?
The acquisition was announced on March 5, 2024.
What type of company is Tandem Diabetes Care?
Tandem Diabetes Care, Inc. is a company in the diabetes care sector, likely focused on technology or devices.
Filing Stats: 540 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-03-05 21:55:47
Key Financial Figures
- $300 million — that it had (i) priced its offering of $300 million aggregate principal amount of convertib
Filing Documents
- livn-20240305.htm (8-K) — 25KB
- march52024pressrelease-pri.htm (EX-99.1) — 26KB
- downloada03.jpg (GRAPHIC) — 25KB
- livn-20240305_g1.jpg (GRAPHIC) — 7KB
- 0001639691-24-000031.txt ( ) — 237KB
- livn-20240305.xsd (EX-101.SCH) — 2KB
- livn-20240305_lab.xml (EX-101.LAB) — 22KB
- livn-20240305_pre.xml (EX-101.PRE) — 13KB
- livn-20240305_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 5, 2024, LivaNova PLC announced that it had (i) priced its offering of $300 million aggregate principal amount of convertible senior notes due 2029, and (ii) entered into privately negotiated capped call transactions with certain financial institutions. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits. Exhibit Description 99.1 Press Release of LivaNova PLC dated March 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LivaNova PLC Date: March 5, 2024 By: /s/ Michael Hutchinson Name: Michael Hutchinson Title: SVP, Company Secretary & Chief Legal Officer